Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.05.2017 | main topic | Ausgabe 7-8/2017 Open Access

Wiener Medizinische Wochenschrift 7-8/2017

Modulation of gastrointestinal motility beyond metoclopramide and domperidone

Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders

Wiener Medizinische Wochenschrift > Ausgabe 7-8/2017
Ahmed Madisch, Bettina R. Vinson, Heba Abdel-Aziz, Olaf Kelber, Karen Nieber, Karin Kraft, Prof. Dr. med. Martin Storr


The prokinetic cisapride, an important therapeutic option in functional gastrointestinal (GI) disorders, was withdrawn from the market 15 years ago due to rare severe side effects. Likewise in 2014, the use of metoclopramide (MCP) and domperidone in functional GI disorders (FGID) was restricted, consequently leaving a therapeutic gap in clinical practice. A systematic review revealed that the herbal medicinal product (HMP) STW 5 presents a therapeutic option equivalent to MCP and cisapride. STW 5 is the only HMP for which efficacy has been shown in randomized controlled clinical trials (RCTs) in functional dyspepsia and irritable bowel syndrome, based on its multitarget effect on numerous etiological factors. Due to an outstanding favorable safety profile, STW 5 allows an effective and safe use in FGID without a limitation of the duration of the treatment.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 7-8/2017

Wiener Medizinische Wochenschrift 7-8/2017 Zur Ausgabe